## RVTY: Revvity, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.66 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-4.1% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($90.36)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 3, Bearish: 1)

**1. Subscribe to intelligence: R&D’s move towards MaaS**
- Source: R&D World | 20251216T194716 | Bullish | Relevance: 100%
- Revvity has launched Signals Xynthetica, a new Model-as-a-Service (MaaS) platform designed to democratize predictive modeling in R&D. This allows labs to access pre-trained, high-fidelity models, integrate AI tools into experimental workflows, and enhance security by keeping data in-house. The MaaS market, including offerings from AWS and Google, reached $17 billion in 2024 and is projected to grow significantly to $491.5 billion by 2035.

**2. Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery**
- Source: PharmiWeb.com | 20251216T160813 | Bullish | Relevance: 100%
- Revvity, Inc. announced the forthcoming introduction of its Signals Xynthetica™ Models-as-a-Service (MaaS) AI offering, designed to augment molecular and materials design. This platform integrates in-silico generation, predictive modeling, and experimental validation in a single environment, aiming to accelerate scientific innovation by connecting AI predictions with real wet-lab outcomes. The offering addresses the gap between powerful AI models and their real-world impact by embedding models directly into scientific workflows.

**3. Revvity (NYSE: RVTY) unveils Signals Xynthetica AI MaaS for discovery workflows**
- Source: Stock Titan | 20251216T130254 | Bullish | Relevance: 100%
- Revvity, Inc. (NYSE: RVTY) has introduced its new Signals Xynthetica™ Models-as-a-Service (MaaS) AI offering within the Revvity Signals platform. This AI-augmented design platform aims to integrate in-silico generation, predictive modeling, and experimental validation to accelerate molecular and materials discovery. The platform addresses the gap between powerful AI algorithms and their real-world impact by seamlessly connecting AI predictions with experimental data in scientific workflows.

**4. Barclays Adjusts Price Target on Revvity to $115 From $105, Maintains Overweight Rating**
- Source: marketscreener.com | 20251215T150842 | Somewhat-Bullish | Relevance: 100%
- Barclays has increased its price target for Revvity to $115 from $105, while reiterating an Overweight rating on the stock. This adjustment comes amidst other analyst activities, including Wells Fargo also raising its price target and BofA Securities downgrading the stock. Revvity specializes in medical diagnosis and analytical equipment, with significant operations in the US and China.

**5. Revvity stock rating downgraded to Neutral by BofA Securities**
- Source: Investing.com | 20251215T130845 | Bearish | Relevance: 100%
- BofA Securities downgraded Revvity Inc (NYSE:RVTY) from Buy to Neutral, citing limited upside potential due to challenges in its China diagnostics business and a modest 2026 outlook. Despite the downgrade, the new price target of $110.00 still suggests a 9.5% upside from current levels. The firm recommends investors explore other opportunities in the tools sector for now, despite Revvity exceeding Q3 EPS expectations and acquiring ACD/Labs.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $115 | $105 | +10% |
| 2025-12-15 | Wells Fargo | $107 | $102 | +5% |
| 2025-12-09 | Goldman Sachs | $105 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-09 | Goldman Sachs | init | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- T. Rowe Price Invest: 19.9% (-0.6%)
- Vanguard Group Inc: 11.9% (-4.0%)
- Blackrock Inc.: 8.2% (+4.4%)
- Edgepoint Investment: 7.6% (+26.3%)
- Price (T.Rowe) Assoc: 7.2% (+2.4%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.1% 5d) with bearish MACD, trend may be turning.
2. Elevated short interest (9.1%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.66 indicates undervaluation relative to growth. Forward P/E 18.3x stretched relative to 8% growth. Analyst sentiment positive (2 raises, avg +7%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.2B |
| Beta | 1.06 |
| 52W Range | $81.36 - $128.29 |
| Short Interest | 9.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.66 |
| Forward P/E | 18.3 |
| Current P/E | 19.7 |
| YoY Growth | 7.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.4% to -1.7% (-4.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.7pp (needs >4.0% for momentum thesis). AM_20 at -3.7% indicates price below own 20MA trend. Underperforming sector by 3.4pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.02x) but short-term weakness (below SMA20). MACD histogram bearish (-0.87), momentum weakening. RSI neutral at 46. OFD pattern: +DUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.71% (CS: 18) | Neutral |
| RSI_14 | 45.9 | Neutral |
| MACD Histogram | -0.87 | Bearish |
| vs SMA20 | 0.963x | Below |
| vs SMA50 | 1.006x | Above |
| vs SMA200 | 1.018x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $96.82
- **Stop Loss:** $90.36 (6.7% risk)
- **Target:** $109.74 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 167
- **Position Value:** $16,168.94
- **Portfolio %:** 16.17%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-01-26 (Est: $1.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.14 | $1.18 | +3.6% |
| 2025Q2 | $1.14 | $1.18 | +3.4% |
| 2025Q1 | $0.95 | $1.01 | +6.4% |
| 2024Q4 | $1.38 | $1.42 | +3.1% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_20*